Status:
TERMINATED
Alexa, What is Eliquis and Xarelto?
Lead Sponsor:
Cedars-Sinai Medical Center
Conditions:
Patient Engagement
Patient Satisfaction
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to evaluate the effectiveness of providing patient medication education about Eliquis and Xarelto through an Amazon Alexa based voice recording.
Detailed Description
Anticoagulants are considered high-risk medications due to the risk of major bleeding. The Federal Drug and Food Administration (FDA) MedWatch reporting system found that anticoagulants had the most a...
Eligibility Criteria
Inclusion
- Inclusion Criteria (Patients):
- 18 years of age or older
- Have been prescribed either apixaban or rivaroxaban during their inpatient stay
- Consent to participating in the study
- Inclusion Criteria (Nurses):
- Providing direct patient care in select general medicine and orthopedic surgical units
- Consent to participating in the study
- Exclusion Criteria:
- Patients will be excluded if they have documented altered mental status, do not speak English, or are being prescribed rivaroxaban or apixaban on discharge only.
- Nurses will be excluded if not providing direct patient care in select general medicine and orthopedic surgical units
- Nurses declining participation
Exclusion
Key Trial Info
Start Date :
May 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2021
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04790773
Start Date
May 21 2021
End Date
October 31 2021
Last Update
March 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048